Subject(s)
Adaptor Proteins, Signal Transducing , Transcription Factors , YAP-Signaling Proteins , Humans , Transcription Factors/genetics , Adaptor Proteins, Signal Transducing/genetics , Prognosis , Oncogene Proteins, Fusion/genetics , Female , Cell Differentiation , Biomarkers, Tumor/genetics , MaleABSTRACT
The dedifferentiation of the gastrointestinal stromal tumors (GISTs) has been reported in a small number of cases, usually under the pressure of the tyrosine kinase inhibitor (TKI) treatment. Herein, we described a de novo dedifferentiated GIST with the SDH deficiency in a 32-year-old Chinese woman. The tumor was located on the lesser curvature of the gastric antrum, measuring 4.1x9.1 cm2. Microscopically, the tumor was composed of 2 distinct morphological populations, mild epithelioid cells arranged in the multinodular growth pattern and hyperchromatic spindle cells arranged in the fascicular or sheet-like architecture. The two zones showed different immunophenotypes. The former proved to be an epithelioid GIST with the positive expression for C-KIT, DOG-1, and CD34, and the latter expressed the CKpan and P53, but negative for the C-KIT, DOG-1, and CD34. However, the SDHB staining was negative in both areas. Genetically, the next-generation sequencing (NGS) analysis showed the SDHC mutation (p.S48*) in both components and the MDM2 amplification was only in the spindle cell area. The lesion was diagnosed as the SDH-deficient GIST with the epithelial cell dedifferentiation. We proposed that the P53 associated gene alteration or other alternative escape mechanisms for the KIT-independent signaling pathways might play a role in the dedifferentiation.
ABSTRACT
Introduction: Solitary fibrous tumor (SFT) represents a fibroblastic neoplasm exhibiting NAB2::STAT6 gene rearrangement, displaying diverse clinical manifestations, spanning from benign to malignant. To predict prognosis, the modified (four-variable) Demicco (mDemicco) model was introduced. This investigation aims to authenticate the mDemicco risk model's precision in Asian patients while investigating the clinicopathological and molecular factors linked to the prognosis of extrameningeal SFTs. Methods: Clinicopathological data from 111 extrameningeal SFT cases in East China, covering the period from 2010 to 2020, were thoroughly analyzed. The tumors were classified using the mDemicco model. Immunohistochemical evaluation of P16 and P53, molecular detection of TP53 and TERT promoter mutation, and fluorescence in situ hybridization for CDKN2A gene alterations were performed. Statistical methods were utilized to assess the associations between clinicopathological or molecular factors and prognosis. Results: Histologically, only one parameter, the mitotic count, exhibited a statistical correlation with progression-free survival (PFS) and overall survival (OS). During the Kaplan-Meier analysis, the variation in PFS among the different risk groups exhibited a notable trend towards statistical significance. Nevertheless, 3 out of 74 patients classified as low-risk SFTs and 7 out of 21 patients classified as intermediate-risk exhibited disease progression. Among the 5 patients with TP53 mutations and/or mutant-type P53 immunophenotype, 3 experienced disease progression, including 2 intermediate-risk patients. Additionally, among the 4 patients with TERT promoter mutations who were followed up, 3 showed progression, including 2 intermediate-risk patients. Moreover, it was observed that hemizygous loss of CDKN2A was detected in more than 30% of one case, yet the patient exhibited a favorable survival outcome. Conclusion: The mDemicco risk model exhibits certain limitations when dealing with smaller tumor sizes, younger age groups, and occurrences of malignant and dedifferentiated SFTs. Furthermore, molecular factors, such as TP53 or TERT promoter mutations, may identify intermediate-risk SFTs with poorer prognoses.
ABSTRACT
ALK rearrangements have rarely been reported in S100- and CD34-co-expressing soft tissue neoplasms with lipofibromatosis-like neural tumor (LPFNT) pattern or stromal and perivascular hyalinization, mimicking NTRK-rearranged spindle cell tumors. Here, we reported ALK fusions involving related partner genes in two adult soft tissue tumors with S100 and CD34 co-expression, and conducted a literature review of mesenchymal tumors harboring ALK or other kinase fusions. Case 1 was a 25-year-old female who underwent excision of a soft tissue mass in the anterior thigh region. Morphologically, the tumor was composed of spindle cells adjacent to epithelioid cells embedded in myxedematous and hyalinized stroma, with infiltrative boundary. Spindle cells mixed with inflammatory infiltration resembling inflammatory myofibroblastic tumor (IMT) were seen sporadically. However, brisk mitosis and focal necrosis was also observed, indicating an intermediate-grade sarcoma. In case 2, the left side of the neck of a 34-year-old man was affected. The tumor was composed of monomorphic spindle cells arranged in fascicular growth or patternless pattern, with stromal and perivascular hyalinization. Sparse inflammatory cell infiltration was also observed. Both tumors showed CD34, S100, and ALK-D5F3 immunoreactivity. Next generation sequencing (NGS) test identified a PLEKHH2::ALK fusion in case 1, which was confirmed by RT-PCR and Sanger sequencing, whereas the RT-PCR (ARMS method) test detected an EML4::ALK fusion in case 2. In conclusion, this study expands the morphological and genetic landscape of tumors with S100 and CD34 co-expression harboring kinase fusions, and suggests that kinase fusion-positive mesenchymal neoplasms are becoming an enlarging entity with a variety of morphological patterns.
ABSTRACT
A 34-year-old Chinese woman found a lump in her left leg for more than 3 weeks without any discomfort. Grossly, the tumor was relatively well delineated with focal infiltration. Histopathologic evaluation showed a compact fascicular spindle cell proliferation with variable myxoid and collagenous stroma and scattered inflammatory infiltrate. Immunohistochemically, the tumor cells showed positive expression of ALKD5F3 and SMA and negative expression of CD34, desmin, and cytokeretin. Fluorescence in situ hybridization analysis of the ALK locus showed break-apart signals in 20% of tumor cells, and DNA sequencing discovered a novel CLIP2-ALK fusion gene. The lesion was diagnosed as an inflammatory myofibroblastic tumor (IMT). To the best of our knowledge, this is the first case with CLIP2-ALK gene fusion in the somatic soft tissue IMTs.
Subject(s)
Anaplastic Lymphoma Kinase/genetics , Microtubule-Associated Proteins/genetics , Neoplasms, Muscle Tissue/diagnostic imaging , Soft Tissue Neoplasms/diagnostic imaging , Adult , Anaplastic Lymphoma Kinase/metabolism , Female , Gene Fusion , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Leg/diagnostic imaging , Leg/pathology , Microtubule-Associated Proteins/metabolism , Neoplasms, Muscle Tissue/genetics , Neoplasms, Muscle Tissue/pathology , Soft Tissue Neoplasms/genetics , Soft Tissue Neoplasms/pathologyABSTRACT
Recently, a novel group of spindle cell tumors defined by S100 and CD34 co-expression harboring recurrent fusions involving RET, RAF1, BRAF, and NTRK1/2 gene has been identified. Morphologically, they are characterized by monomorphic neoplasm cells, "patternless" growth pattern, stromal, and perivascular hyalinization, lacked necrosis. We reported a 52-year-old Chinese female patient with a S100 and CD34 co-expression sarcoma presenting in the right proximal forearm. The forearm mass initially emerged 19 months ago when it was misdiagnosed as a solitary fibrous tumor and was surgically removed without further treatment. Microscopically, the primary and the recurred tumors share the same features, resembling the morphology of the recently characterized group. Nevertheless, some distinct features, such as predominantly epithelioid tumor cells and focally staghorn vessels, were also present in our case. Genomic profiling with clinical next-generation sequencing was performed and revealed CDC42SE2-BRAF gene fusion, MET amplification, and CDKN2A/B deletion. Both FISH and nested RT-PCR were performed to confirm the gene fusion. The patient was treated with crizotinib for two cycles but showed no obvious benefit. The presented case adds to the spectrum of the novel, characterized solid tumors, and provides suggestions for emerging therapeutic strategies for precision medicine involving targeted kinase inhibitors.
Subject(s)
Antigens, CD34/genetics , Intracellular Signaling Peptides and Proteins/genetics , Membrane Proteins/genetics , Oncogene Proteins, Fusion/genetics , Proto-Oncogene Proteins B-raf/genetics , S100 Proteins/genetics , Soft Tissue Neoplasms/genetics , Antigens, CD34/metabolism , Cyclin-Dependent Kinase Inhibitor p16/genetics , Female , Gene Deletion , Gene Dosage , Humans , Middle Aged , Neoplasm Grading , Proto-Oncogene Proteins c-met/genetics , S100 Proteins/metabolism , Soft Tissue Neoplasms/pathologyABSTRACT
AIM: CD30+ diffuse large B-cell lymphoma (DLBCL) has emerged as a new immunophenotypic variant of de novo DLBCLs. However, the prevalence of CD30 positivity is variable according to different studies, and the prognostic significance of CD30 is also controversial. This study aimed to investigate the positive expression rate and prognostic impact of CD30 in de novo DLBCLs and try to find the correlated influences. METHODS: A total of 241 patients with de novo DLBCL in east China from 2008 to 2015 were included to investigate the prevalence, clinicopathological features and outcomes of CD30+ de novo DLBCLs. Immunohistochemical evaluation for CD10, CD30, BCL2, BCL6, MUM1/IRF4, MYC and Ki67, and fluorescence in situ hybridisation for MYC and BCL2 gene alterations were performed. RESULTS: Using a >0% threshold, CD30 expression was detected in approximately 10% patient with de novo DLBCL. These predominately presented with centroblastic or anaplastic morphological patterns, less frequently showing immunoblastic morphology or 'starry sky' pattern, mutually exclusive with MYC gene rearrangement, and negatively associated with BCL2 protein expression. CD30 expression was associated with a favourable prognosis of patients' outcomes. However, the multivariate analysis revealed that it was not an independent prognostic factor in de novo DLBCLs. The impact of CD30 might be influenced by the international prognostic index and the expression of MYC and BCL2 proteins. CONCLUSION: CD30+ DLBCL may be a subset of de novo DLBCLs with characteristic clinicopathological features, but the prognostic role of CD30 is limited.
Subject(s)
Biomarkers, Tumor/analysis , Ki-1 Antigen/analysis , Lymphoma, Large B-Cell, Diffuse/chemistry , Proto-Oncogene Proteins c-bcl-2/analysis , Proto-Oncogene Proteins c-myc/analysis , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/genetics , Chi-Square Distribution , China , Female , Gene Rearrangement , Genetic Predisposition to Disease , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Kaplan-Meier Estimate , Lymphoma, Large B-Cell, Diffuse/genetics , Lymphoma, Large B-Cell, Diffuse/pathology , Male , Middle Aged , Multivariate Analysis , Phenotype , Predictive Value of Tests , Prognosis , Proportional Hazards Models , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-myc/genetics , Retrospective Studies , Risk Factors , Young AdultABSTRACT
Using an immunohistochemistry (IHC) based method, diffuse large B-cell lymphoma (DLBCL) can be classified into germinal center B-cell (GCB) and non-GCB subtypes. However, the prognostic value of Hans algorithm was contradictory in the literature. Using IHC and fluorescence in situ hybridization, we analyzed the antibodies applied in Hans algorithm and other genetic factors in 601 DLBCL patients and prognostic value of Hans algorithm in 306 cases who were treated with chemoimmunotherapy. The results showed that patients with GCB subtype have better overall survival (OS) and progression-free survival (PFS) than non-GCB cases. However, to some extent, double positive (CD10(+)MUM1(+), DP) and triple negative (CD10(-)Bcl6(-)MUM(-), TN) showed different clinical characteristics and prognosis to others that were assigned to the same cell-of-origin group. The DP group showed similar OS (median OS: both not reached, P = 0.3650) and PFS (median PFS: 47.0 vs. 32.7 months, P = 0.0878) with the non-GCB group while the TN group showed similar OS (median OS: both not reached, P = 0.9278) and PFS (median PFS: both not reached, P = 0.9420) with the GCB group. In conclusion, Recognition of specific entities in Hans algorithm could help us to accurately predict outcome of the patients and choose the best clinical management for them.
Subject(s)
Algorithms , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Biomarkers/blood , Interferon Regulatory Factors/blood , Lymphoma, Large B-Cell, Diffuse , Neprilysin/blood , Proto-Oncogene Proteins c-bcl-6/blood , Adolescent , Adult , Aged , Aged, 80 and over , Disease-Free Survival , Female , Humans , Lymphoma, Large B-Cell, Diffuse/blood , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/mortality , Male , Middle Aged , Survival RateABSTRACT
Epstein-Barr virus (EBV) positive diffuse large B-cell lymphoma (DLBCL) of the elderly is defined as patients older than 50 years alone. However, recent studies showed young patients with sound immune status could also be affected. In this study, we investigated the clinical features and outcomes of patients with EBV positive DLBCL in the different age groups using different EBER cut-off values. The prevalence of EBV positive DLBCL was 14.0% (35/250) and 10.4% (26/250) for EBER cut-off of 20% and 50%, respectively. With both EBER cut-off values, patients with EBV DLBCL shared many unfavorable prognostic characteristics, regardless of age. EBV positive patients, both in the elderly and young groups, showed significantly worse overall survival and progression-free survival than negative cases. Moreover, no significant differences of outcomes were identified between different age groups with EBV positive DLBCL. In conclusion, EBV positive DLBCL patients, regardless of age, shared similar poor prognostic features and showed worse outcome than negative cases. We suggest that the age criterion of EBV positive DLBCL of the elderly, and possibly the name itself, be modified in future.
Subject(s)
Herpesvirus 4, Human/isolation & purification , Lymphoma, B-Cell/mortality , Lymphoma, B-Cell/virology , Lymphoma, Large B-Cell, Diffuse/mortality , Lymphoma, Large B-Cell, Diffuse/virology , Age Distribution , Aged , Aged, 80 and over , China/epidemiology , Comorbidity , Disease-Free Survival , Female , Humans , Incidence , Male , Middle Aged , Prognosis , Reproducibility of Results , Risk Factors , Sensitivity and Specificity , Sex Distribution , Survival RateABSTRACT
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL). Patients with DLBCL harboring MYC aberrations concurrent with BCL2 or/and BCL6 aberrations constitute a specific group with extremely poor outcome. In this study, we retrospectively investigated the incidence and prognosis of MYC, BCL2, and BCL6 aberrations with DLBCL patients in Chinese population. We applied fluorescence in situ hybridization and immunohistochemical analysis in 246 DLBCL patients. The results showed that patients with MYC or BCL2 copy number aberration (CNA) had significantly worse overall survival (OS) and progression-free survival (PFS) than negative cases (P < 0.0001). Patients with both MYC and BCL2 CNA had similar outcomes to those with classic double hit lymphoma or protein double expression lymphoma (MYC and BCL2/BCL6 coexpression). By multivariate analysis, MYC CNA, BCL2 CNA and double CNA were the independent worse prognostic factors. In conclusions, patients with MYC or BCL2 CNA constituted a unique group with extremely poor outcome and may require more aggressive treatment regimens.
Subject(s)
DNA Copy Number Variations , Genetic Predisposition to Disease/genetics , Lymphoma, Large B-Cell, Diffuse/genetics , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-myc/genetics , Adult , Asian People/genetics , China/epidemiology , Disease-Free Survival , Female , Genetic Predisposition to Disease/ethnology , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Incidence , Lymphoma, Large B-Cell, Diffuse/epidemiology , Lymphoma, Large B-Cell, Diffuse/ethnology , Male , Middle Aged , Multivariate Analysis , Prognosis , Proto-Oncogene Proteins c-bcl-2/metabolism , Proto-Oncogene Proteins c-myc/metabolism , Retrospective StudiesABSTRACT
Gene expression profiling (GEP), which can divide DLBCL into three groups, is impractical to perform routinely. Although algorithms based on immunohistochemistry (IHC) have been proposed as a surrogate for GEP analysis, the power of them has diminished since rituximab added to the chemotherapy. We assessed the prognostic value of four conventional algorithms and the genes in each and out of algorithm by IHC and fluorescence in situ hybridization in DLBCL patients receiving immunochemotherapy. The results showed that neither single protein within algorithms nor the IHC algorithms themselves had strong prognostic power. Using MYC aberrations (MA) either on the genetic or protein levels, we established a new algorithm called MA that could divide patients into distinct prognostic groups. Patients of MA had much shorter overall survival (OS) and progression-free survival (PFS) than non-MA (2-year OS: 56.9% vs. 98.7%; 2-year PFS: 26.8% vs. 86.9%; P < 0.0001 for both). In conclusions, using additional prognostic markers not associated with cell of origin may accurately predict outcomes of DLBCL. Studies with larger samples should be performed to confirm our algorithm and optimize the prognostic system of DLBCL.
Subject(s)
Algorithms , Biomarkers, Tumor/analysis , Lymphoma, Large B-Cell, Diffuse/drug therapy , Aged , Antibodies, Monoclonal, Murine-Derived , Antineoplastic Combined Chemotherapy Protocols , Cyclophosphamide , Doxorubicin , Female , Gene Expression Profiling , Genes, myc , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Kaplan-Meier Estimate , Lymphoma, Large B-Cell, Diffuse/genetics , Lymphoma, Large B-Cell, Diffuse/mortality , Male , Middle Aged , Prednisone , Prognosis , Retrospective Studies , Rituximab , Treatment Outcome , VincristineABSTRACT
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease that great efforts had been made in to build up molecular and immunophenotypic subgroups that could relatively accurate indicate prognosis and give clue to therapy. Recently, CD30 was reported as a useful predictor with favorable clinical outcome. However, CD30 expression patterns and the clinicopathologic features of CD30 positive DLBCL are not well described thus far, especially in Asian patients. Here, we studied 232 cases of de novo DLBCL in East China to investigate the prevalence and clinicopathological features of CD30-positive DLBCL using a panel of immunohistochemical markers. Applying a >0% threshold, CD30 was expressed in approximately 12% patients with Epstein-Barr virus (EBV) negative DLBCL, affecting younger people and showing a lower frequency of BCL2 expression and MYC/BCL2 co-expression. Patients with CD30-positive DLBCLs showed better progression-free survival and overall survival compared with patients with CD30-negative DLBCLs, although the superior outcome of CD30 positivity had minimal effects on BCL2+ DLBCL or DLBCL with MYC/BCL2 co-expression. Moreover, CD30 could express in CD5+ DLBCL. We concluded that CD30 may be useful as a prognostic marker in rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treated DLBCLs, indicating favorable outcomes in a Chinese population. Further studies with larger samples should be performed to investigate the function of CD30 expression in BCL2+ DLBCLs, DLBCLs with MYC/BCL2 co-expression, and CD5+ DLBCLs, and to evaluate the feasibility of anti-CD30 targeted treatment in DLBCL therapy.
Subject(s)
Biomarkers, Tumor/analysis , Ki-1 Antigen/analysis , Lymphoma, Large B-Cell, Diffuse/chemistry , Adult , Aged , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Asian People , CD5 Antigens/analysis , China , Cyclophosphamide/therapeutic use , Disease-Free Survival , Doxorubicin/therapeutic use , Female , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/ethnology , Lymphoma, Large B-Cell, Diffuse/pathology , Male , Middle Aged , Predictive Value of Tests , Prednisone/therapeutic use , Prevalence , Proto-Oncogene Proteins c-bcl-2 , Proto-Oncogene Proteins c-myc , Retrospective Studies , Risk Factors , Rituximab , Time Factors , Treatment Outcome , Vincristine/therapeutic use , Young AdultABSTRACT
OBJECTIVE: To study the clinicopathologic features, diagnosis and differential diagnosis of epithelioid hemangioma. METHODS: The morphologic features of 7 cases of epithelioid hemangioma of skin, bone and venous vessels were studied. RESULTS: There were altogether 4 male and 3 female patients (median age = 34 years; age range from 14 to 54 years). The 3 skin cases presented as single or multiple erythematous to bluish nodules or papules, with or without itchiness. The 2 bone cases appeared as osteolytic expansile lesions on radiologic examination. The remaining 2 cases involved medium-sized venous structures and presented as small isolated nodules in soft tissue. Histologically, the lesions were characterized by the presence of exuberant endothelial proliferations with various degree of inflammatory reaction. The neoplastic endothelial cells were plump, eosinophilic and polygonal, forming vascular channels. Occasional solid sheet-like arrangement was demonstrated. Intracytoplasmic vacuoles were commonly identified, indicating formation of primary lumen. The surrounding stroma contained various number of eosinophils and lymphoplasmacytic cells. Immunohistochemical study showed that the tumor cells were positive for endothelial markers (CD31 and CD34) and negative for epithelial marker (cytokeratin). Follow-up information was available in 6 cases. The duration of follow-up ranged from 5 to 36 months (median = 14 months). There was no evidence of recurrence or distant metastasis. CONCLUSIONS: Epithelioid hemangioma is a rare benign curable lesion which can be multifocal, involving skin, soft tissue and bone. It needs to be distinguished from Kimura's disease and epithelioid hemangioendothelioma.
Subject(s)
Bone Neoplasms/pathology , Hemangioma/pathology , Skin Neoplasms/pathology , Adolescent , Adult , Angiolymphoid Hyperplasia with Eosinophilia/pathology , Antigens, CD34/metabolism , Bone Neoplasms/metabolism , Bone Neoplasms/surgery , Diagnosis, Differential , Female , Follow-Up Studies , Hemangioendothelioma, Epithelioid/pathology , Hemangioma/metabolism , Hemangioma/surgery , Humans , Male , Middle Aged , Platelet Endothelial Cell Adhesion Molecule-1/metabolism , Skin Neoplasms/metabolism , Skin Neoplasms/surgerySubject(s)
Soft Tissue Neoplasms/pathology , Cell Differentiation , Child , Dermatofibrosarcoma/metabolism , Dermatofibrosarcoma/pathology , Diagnosis, Differential , Humans , Immunohistochemistry , Infant , Lipoblastoma/metabolism , Lipoblastoma/pathology , Liver Neoplasms/metabolism , Liver Neoplasms/pathology , Mesenchymoma/metabolism , Mesenchymoma/pathology , Neoplasms, Germ Cell and Embryonal/metabolism , Neoplasms, Germ Cell and Embryonal/pathology , Sarcoma/metabolism , Sarcoma/pathology , Skin Neoplasms/metabolism , Skin Neoplasms/pathology , Soft Tissue Neoplasms/metabolismSubject(s)
Breast Neoplasms/pathology , Carcinoma/pathology , Hemangiosarcoma/pathology , Leiomyosarcoma/pathology , Soft Tissue Neoplasms/pathology , Uterine Neoplasms/pathology , Adolescent , Adult , Diagnosis, Differential , Endothelium, Vascular/pathology , Fasciitis/pathology , Female , Histiocytoma, Malignant Fibrous/pathology , Humans , Hyperplasia/pathology , Leiomyoma/pathology , Middle Aged , Vascular Diseases/pathologySubject(s)
Breast Neoplasms/pathology , Carcinoma/pathology , Fibroma/pathology , Actins/metabolism , Aged , Breast Neoplasms/metabolism , Breast Neoplasms/surgery , Carcinoma/metabolism , Carcinoma/surgery , Diagnosis, Differential , Fasciitis/metabolism , Fasciitis/pathology , Female , Fibroma/metabolism , Fibroma/surgery , Humans , Keratin-5/metabolism , Mastectomy, Modified Radical , Neoplasms, Muscle Tissue/metabolism , Neoplasms, Muscle Tissue/pathologyABSTRACT
OBJECTIVE: To improve the understanding of progressive transformation of lymph node germinal centers (PTGC) and to explore its clinical, histopathologic and immunohistochemical features and the differential diagnosis between the related disease of germinal center hyperplasia. METHODS: The clinical manifestation, laboratory bindings, treatment and outcome of a patient with PTGC were presented. RESULTS: The main manifestation of the patient was painless peripheral lymphadenopathy. Histopathologic examination of an axillary lymph node showed reactive follicular hyperplasia and the progressive transformation changes germinal centers. The borderline between the germinal center and the mantle layer was obscured. The cells in the progressive transforming germinal centers were positive for CD20(+), CD5(+), CDw75(+). CONCLUSION: PTGC is a rare lymphoid disorder. Histopathology and immunohistochemistry are important basis of the diagnosis.
Subject(s)
Germinal Center , Lymphatic Diseases , Diagnosis, Differential , Humans , Hyperplasia , Lymph NodesSubject(s)
Digestive System Neoplasms/pathology , Kidney Neoplasms/pathology , Perivascular Epithelioid Cell Neoplasms/pathology , Skin Neoplasms/pathology , Soft Tissue Neoplasms/pathology , Uterine Neoplasms/pathology , Carcinoma, Renal Cell/pathology , Diagnosis, Differential , Female , Gastrointestinal Stromal Tumors/pathology , Humans , Leiomyoma/pathology , Male , Melanoma/pathology , Sarcoma, Clear Cell/pathology , Sarcoma, Endometrial Stromal/pathologyABSTRACT
OBJECTIVE: To study the pathological characteristics, diagnosis and differential diagnoses of hemangiopericytoma-solitary fibrous tumor with giant cells. METHODS: Pathological characteristics of seven cases of orbital and extraorbital hemangiopericytoma-solitary fibrous tumors with giant cells were evaluated by HE and immunohistochemistry (EnVision method). RESULTS: Two cases were located in the orbit, one of which had recurred. Five cases were located in the extraorbital regions. Histologically, the tumors were well-circumscribed and composed of non-atypical, round to spindle cells with collagen deposition in the stroma. The tumors had prominent vasculatures and in areas, pseudovascular spaces lined by multinucleated giant cells lining which were also present in the stroma. Immunohistochemically, both neoplastic cells and multinucleate giant cells expressed CD34. Seven patients underwent tumor excision and were well and without tumor recurrence upon the clinical follow-up. CONCLUSIONS: Hemangiopericytoma-solitary fibrous tumor with giant cells is an intermediate soft tissue tumor. It typically involves the orbital or extraorbital regions. Histologically, the tumor should be distinguished from giant cell fibroblastoma, pleomorphic hyalinzing angiectatic tumor of soft part and angiomatoid fibrous histiocytoma.
Subject(s)
Hemangiopericytoma/pathology , Orbital Neoplasms/pathology , Solitary Fibrous Tumors/pathology , 12E7 Antigen , Adult , Antigens, CD/metabolism , Antigens, CD34/metabolism , Cell Adhesion Molecules/metabolism , Dermatofibrosarcoma/pathology , Diagnosis, Differential , Female , Follow-Up Studies , Hemangiopericytoma/metabolism , Hemangiopericytoma/surgery , Histiocytoma, Benign Fibrous/pathology , Humans , Immunohistochemistry , Male , Middle Aged , Neoplasm Recurrence, Local , Orbital Neoplasms/metabolism , Orbital Neoplasms/surgery , Proto-Oncogene Proteins c-bcl-2/metabolism , Soft Tissue Neoplasms/pathology , Solitary Fibrous Tumor, Pleural/metabolism , Solitary Fibrous Tumor, Pleural/pathology , Solitary Fibrous Tumor, Pleural/surgery , Solitary Fibrous Tumors/metabolism , Solitary Fibrous Tumors/surgery , Young AdultABSTRACT
OBJECTIVE: To study the clinicopathologic features of inflammatory pseudotumor-like follicular dendritic cell tumor of spleen. METHODS: One case of inflammatory pseudotumor-like follicular dendritic cell tumor of spleen was examined macroscopically and microscopically. Immunohistochemical study for CD21, CD23, CD35, clusterin, S-100 protein, vimentin, smooth muscle actin, CD1a, CD68, ALK protein, CD30, CD31, CD34, CD3 and CD20 was performed on formalin-fixed, paraffin-embedded sections by standard EnVision method. In-situ hybridization for Epstein-Barr virus (EBV)-encoded RNA was also carried out. RESULTS: Macroscopically, inflammatory pseudotumor-like follicular dendritic cell tumor was large in size, tan-colored, soft to rubbery in consistance and associated with central hemorrhage and necrosis. Histological examination showed scattered follicular dendritic cells admixed with abundant lymphocytes and plasma cells in the background, simulating inflammatory pseudotumor. On high-power magnification, the follicular dendritic cells possessed a moderate amount of pale to lightly eosinophilic cytoplasm, with indistinct cell borders. The nuclei were ovoid or spindly, with vesicular or stippled chromatin and small distinct, often centrally located, nucleoli. Some of the tumor cells showed nuclear pleomorphism and contained irregular foldings of nuclear membrane, coarse chromatin and prominent eosinophilic nucleoli. Mitotic figures were rarely identified. Immunohistochemical study showed that the tumor cells were positive for vimentin, clusterin, smooth muscle actin and CD68. They were weakly and focally positive for CD35 and S-100 protein, but negative for CD21, CD23, CD1a, ALK protein, CD30, CD31 and CD34. Most of the background lymphocytes were of T-lineage (CD3-positive) ,some were CD20 (B-cell marker)-positive. EBV RNA was demonstrated in the tumor cells by in-situ hybridization analysis. CONCLUSIONS: Inflammatory pseudotumor-like follicular dendritic cell tumor is a rarely encountered low-grade malignancy with distinctive morphologic pattern. It is associated with EBV infection.